Last reviewed · How we verify
N-803
N-803 is a superagonist of the IL-15 receptor that expands and activates natural killer cells and CD8+ T cells to enhance anti-tumor immunity.
N-803 is a superagonist of the IL-15 receptor that expands and activates natural killer cells and CD8+ T cells to enhance anti-tumor immunity. Used for Metastatic melanoma (in combination with checkpoint inhibitors), Renal cell carcinoma, Non-small cell lung cancer.
At a glance
| Generic name | N-803 |
|---|---|
| Also known as | also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803, ALT-803, Anktiva, Nant-803, Formerly known as ALT-803 |
| Sponsor | National Cancer Institute (NCI) |
| Drug class | IL-15 superagonist |
| Target | IL-15 receptor (IL-15R) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
N-803 is an engineered IL-15 superagonist complex designed to preferentially stimulate IL-15 receptor signaling on natural killer (NK) cells and CD8+ T lymphocytes while minimizing activation of regulatory T cells. By amplifying these cytotoxic immune populations, N-803 aims to enhance tumor recognition and destruction. It is being developed as an immunotherapy agent to boost endogenous anti-tumor immune responses.
Approved indications
- Metastatic melanoma (in combination with checkpoint inhibitors)
- Renal cell carcinoma
- Non-small cell lung cancer
Common side effects
- Cytokine release syndrome
- Fatigue
- Fever
- Chills
Key clinical trials
- A Study to Assess Anktiva in Patients With Long Covid-19. (PHASE2)
- Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer (PHASE1, PHASE2)
- Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (PHASE2)
- ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer (PHASE3)
- Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) (PHASE2)
- Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer (PHASE1)
- A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer (PHASE1, PHASE2)
- N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |